Literature DB >> 23889966

Synergistic effects of fresh frozen plasma and valproic acid treatment in a combined model of traumatic brain injury and hemorrhagic shock.

Ayesha M Imam1, Guang Jin, Michael Duggan, Martin Sillesen, John O Hwabejire, Cecilie H Jepsen, Danielle DePeralta, Baoling Liu, Jennifer Lu, Marc A deMoya, Simona Socrate, Hasan B Alam.   

Abstract

INTRODUCTION: Traumatic brain injury (TBI) and hemorrhagic shock (HS) are major causes of trauma-related deaths and are especially lethal as a combined insult. Previously, we showed that early administration of fresh frozen plasma (FFP) decreased the size of the brain lesion and associated swelling in a swine model of combined TBI+HS. We have also shown separately that addition of valproic acid (VPA) to the resuscitation protocol attenuates inflammatory markers in the brain as well as the degree of TBI. The current study was performed to determine whether a combined FFP+VPA treatment strategy would exert a synergistic effect.
METHODS: Yorkshire swine (42-50 kg) were instrumented to measure hemodynamic parameters, intracranial pressure, and brain tissue oxygenation. TBI was created through a 20-mm craniotomy using a computer-controlled cortical impactor: 15-mm cylindrical tip impactor at 4 m/s velocity, 100 ms dwell time, and 12-mm penetration depth. The TBI was synchronized with the initiation of volume-controlled hemorrhage (40 ± 5% of total blood volume). After a 2-hour period of shock, animals were randomized to 1 of 3 resuscitation groups (n = 5 per group): (1) 0.9% saline (NS); (2) FFP; and (3) FFP and VPA 300 mg/kg (FFP+VPA). The resuscitative volume for FFP was equivalent to the shed blood, whereas NS was 3 times this volume. VPA treatment was started 1 hour after hemorrhage. Animals were monitored for 6 hours post-resuscitation. At this time the brains were harvested, sectioned into 5-mm slices, and stained with 2,3,5-triphenyltetrazolium chloride to quantify the lesion size (mm(3)) and brain swelling (percent change compared with the uninjured side).
RESULTS: The combined TBI+HS model resulted in a highly reproducible brain injury. Lesion size and brain swelling (mean value ± standard error of the mean) in the FFP+VPA group (1,459 ± 218 mm(3) and 13 ± 1%, respectively) were less than the NS group (3,285 ± 131 mm(3) [P < .001] and 37 ± 2% [P < .001], respectively), and the FFP alone group (2,160 ± 203 mm(3) [P < .05] and 22 ± 1% [P < .001], respectively).
CONCLUSION: In a large animal model of TBI+HS, early treatment with a combination of FFP and VPA decreases the size of brain lesion and the associated swelling.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23889966     DOI: 10.1016/j.surg.2013.05.008

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  16 in total

Review 1.  Creating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and Future.

Authors:  Ihab Halaweish; Vahagn Nikolian; Patrick Georgoff; Yongqing Li; Hasan B Alam
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

2.  Transcriptomic changes following valproic acid treatment promote neurogenesis and minimize secondary brain injury.

Authors:  Vahagn C Nikolian; Isabel S Dennahy; Gerald A Higgins; Aaron M Williams; Michael Weykamp; Patrick E Georgoff; Hassan Eidy; Mohamed H Ghandour; Panpan Chang; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2018-03       Impact factor: 3.313

3.  Resuscitation speed affects brain injury in a large animal model of traumatic brain injury and shock.

Authors:  Martin Sillesen; Guang Jin; Pär I Johansson; Hasan B Alam
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-08-14       Impact factor: 2.953

Review 4.  Valproic acid: a new candidate of therapeutic application for the acute central nervous system injuries.

Authors:  Sheng Chen; Haijian Wu; Damon Klebe; Yuan Hong; Jianmin Zhang
Journal:  Neurochem Res       Date:  2014-01-31       Impact factor: 3.996

Review 5.  Different resuscitation strategies and novel pharmacologic treatment with valproic acid in traumatic brain injury.

Authors:  Simone E Dekker; Vahagn C Nikolian; Martin Sillesen; Ted Bambakidis; Patrick Schober; Hasan B Alam
Journal:  J Neurosci Res       Date:  2017-07-25       Impact factor: 4.164

6.  Traumatic brain injury may worsen clinical outcomes after prolonged partial resuscitative endovascular balloon occlusion of the aorta in severe hemorrhagic shock model.

Authors:  Aaron M Williams; Umar F Bhatti; Isabel S Dennahy; Nathan J Graham; Vahagn C Nikolian; Kiril Chtraklin; Panpan Chang; Jing Zhou; Ben E Biesterveld; Jonathan Eliason; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2019-03       Impact factor: 3.313

7.  Selective histone deacetylase-6 inhibition attenuates stress responses and prevents immune organ atrophy in a lethal septic model.

Authors:  Ting Zhao; Yongqing Li; Roderick T Bronson; Baoling Liu; George C Velmahos; Hasan B Alam
Journal:  Surgery       Date:  2014-06-16       Impact factor: 3.982

8.  Modern resuscitation of hemorrhagic shock: what is on the horizon?

Authors:  D T Martin; M A Schreiber
Journal:  Eur J Trauma Emerg Surg       Date:  2014-06-17       Impact factor: 3.693

9.  A systematic review of large animal models of combined traumatic brain injury and hemorrhagic shock.

Authors:  Andrew R Mayer; Andrew B Dodd; Meghan S Vermillion; David D Stephenson; Irshad H Chaudry; Denis E Bragin; Andrew P Gigliotti; Rebecca J Dodd; Benjamin C Wasserott; Priyank Shukla; Rachel Kinsler; Sheila M Alonzo
Journal:  Neurosci Biobehav Rev       Date:  2019-06-27       Impact factor: 8.989

10.  A single dose of valproic acid improves neurologic recovery and decreases brain lesion size in swine subjected to an isolated traumatic brain injury.

Authors:  Glenn K Wakam; Ben E Biesterveld; Manjunath P Pai; Michael T Kemp; Rachel L O'Connell; Krishani K Rajanayake; Kiril Chtraklin; Claire A Vercruysse; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2021-11-01       Impact factor: 3.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.